Loading…
← CockpitCompetitor Analysis › 4506.T Sumitomo Pharma Co LtdOpen in the cockpit ↗

Sumitomo Pharma Co Ltd4506.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharmaceutical company developing drugs in psychiatry/neurology, oncology and regenerative medicine.

≈ A mid-size Japanese pharma like a smaller OtsukaMomentum leader 93
Mkt cap
$5.33B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$54.8M
20-day average traded
Fwd P/E
8.6×
forward earnings
ROIC−WACC
+1.7 pp
WACC 5.0%
Hurdle
+4 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥1,894
1D-3.9%
1W-2.1%
1M+1.2%
3M+38.0%
6M+10.8%
YTD-18.3%
1Y-9.2%
ATR %4.7%
52w lowhigh42.4% off high

What Sumitomo Pharma does

Japanese pharmaceutical company developing drugs in psychiatry/neurology, oncology and regenerative medicine.

Earns from prescription drugs sold in Japan and, through its US arm, North America. Its former top seller in the US, Latuda for schizophrenia and bipolar disorder, lost patent protection in 2023, forcing a restructuring around newer products such as Orgovyx and Myfembree.

In one line: A mid-size Japanese pharma like a smaller Otsuka.

Products and services

  • Psychiatry/CNS drugs
  • Oncology drugs
  • Regenerative medicine/cell therapy

Customers

  • Hospitals/physicians prescribing its drugs
  • Patients

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Prescription drug R&D, manufacturing…

What could go right

  • New drug approvals/pipeline progress

What could go wrong

  • Patent cliffs on existing drugs
  • Clinical trial failure risk

Moat: narrow (IP / patents, regulatory licence). Patent-protected drugs generate returns until patent expiry/generic competition, typical for branded pharma.

Headquarters: Osaka, Japan · Founded: 1897 · Employees: 3,123

Named competitors

Sumitomo Pharma at a glance

Size Sumitomo Pharma (4506.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $5.33B, the 231st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,894 on 18 Nov 2026.

Performance Over six months the shares gained 10.8%, against +2.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 10.7% over the last twelve months (peer median +15.3%); the operating margin is 9.6% (peer median 20.6%).

Valuation It trades at 8.6× forward earnings against a peer median of 26.6× (3rd cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20264506.T 117Peer median 103
Six months, rebased to 100: Sumitomo Pharma against the median of its 20 peers (local-currency closes).

Sumitomo Pharma financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥493B¥453B¥399B¥315B¥556B
Revenue growth—+14%+27%-43%—
Gross profit¥262B¥240B¥225B¥157B¥343B
EBITDA¥67.6B¥73.1B¥48.0B¥36.3B¥52.5B
Net income¥46.2B¥107B¥23.6B-¥315B-¥74.5B
Free cash flow¥67.5B¥67.1B¥8.00B-¥253B¥3.47B
Capital expenditure¥4.70B¥7.31B¥13.0B¥15.7B¥12.7B
Total debt¥140B¥224B¥314B¥428B¥346B

Quarterly statements and history in the cockpit →

Sumitomo Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%688578MANELQDA603087326030PTCTIPCALABGLANDABBOTINDIA600079ERASGLAXOLGNDEMCURESUPNMIRM9995IONS4506.T6-month return →1-month return →
Up and to the right = strong over both horizons. Sumitomo Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%10×20×30×40×688578LQDA603087326030PTCTIPCALABGLAND600079TVTXGLAXOEMCURESUPN99954506.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sumitomo Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%688578LQDA326030PTCTIPCALAB600079LGND99954506.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sumitomo Pharma is the large dot.

Sumitomo Pharma competitors and peer comparison

Head to head with its named competitors (4506.T vs 4578.T vs 4523.T vs 4503.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sumitomo Pharma 4506.T$5.33B+11%+11%10%8.6×1.7%
Otsuka Hldgs 4578.T$39.9B+9%+11%18%16.8×1.6%
Eisai 4523.T$9.36B+11%+11%6%26.6×10.7%
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%

How Sumitomo Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sumitomo Pharma against its 20 peers (data as of 18 Nov 2026)
Measure4506.TPeer medianRank in peer set
1-month return+1.2%-2.1%9th highest of 21
6-month return+10.8%+2.9%8th highest of 21
Distance from 52-week high-42.4%-27.9%6th lowest of 21
Revenue growth (TTM)+10.7%+15.3%7th lowest of 19
Operating margin9.6%20.6%5th lowest of 19
Forward P/E8.6×26.6×3rd cheapest of 17
Growth the price implies (Req g, 7 yrs)1.7%6.6%6th least demanding of 16
Growth delivered (Del g)-2.6%+13.3%lowest of 16
Hurdle (Req g minus delivered)+4.2 pp-4.5 pp5th most demanding of 16
ROIC minus cost of capital+1.7 pp+3.8 pp7th lowest of 16
EV / EBITDA13.5×21.5×3rd cheapest of 11
Net debt / EBITDA0.9×-0.7×3rd most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a

Questions

Who are Sumitomo Pharma's main competitors?
Named competitors: Otsuka Holdings (4578.T), Eisai (4523.T), Astellas Pharma (4503.T). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Veradermics (MANE), Liquidia (LQDA), Gan & Lee Pharmaceuticals (603087.SS), SKBP (326030.KS), PTC Therapeutics (PTCT).
Is Sumitomo Pharma expensive compared with its peers?
On forward p/e it trades at 8.6× against a peer median of 26.6×, 3rd cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sumitomo Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +10.8% against +2.9% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.